Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03518320
Title Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Taris Biomedical LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
DuPage Medical Group Hinsdale Illinois 60521 United States Details
University of Rochester Medical Center Rochester New York 14642 United States Details
Duke University Medical Center Durham North Carolina 27710 United States Details
The University of Oklahoma Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Thomas Jefferson University Philadelphia Pennsylvania 19107 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field